Immune checkpoint inhibitor PD-1 pathway is down-regulated in synovium at various stages of rheumatoid arthritis disease progression

Pathologically expanded peripheral T helper cell subset drives B cells in rheumatoid arthritis

(2017) Deepak A. Rao et al.   NATURE

Inflammatory arthritis and sicca syndrome induced by nivolumab and ipilimumab

(2016) Laura C Cappelli et al.   ANNALS OF THE RHEUMATIC DISEASES

Immunomodulatory Activity of Nivolumab in Metastatic Renal Cell Carcinoma

(2016) Toni K. Choueiri et al.   CLINICAL CANCER RESEARCH

Neurological, respiratory, musculoskeletal, cardiac and ocular side-effects of anti-PD-1 therapy

(2016) Lisa Zimmer et al.   EUROPEAN JOURNAL OF CANCER

Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial

(2016) Jonathan E Rosenberg et al.   LANCET

Psoriasis and psoriatic arthritis induced by nivolumab in a patient with advanced lung cancer

(2016) Sarah Law-Ping-Man et al.   RHEUMATOLOGY

Arthritis and Tenosynovitis Associated With the Anti-PD1 Antibody Pembrolizumab in Metastatic Melanoma

(2015) Matthew M. K. Chan et al.   JOURNAL OF IMMUNOTHERAPY

Ipilimumab-induced colitis in patients with metastatic melanoma

(2015) Kara M. De Felice et al.   MELANOMA RESEARCH

Nivolumab versus Docetaxel in Advanced Nonsquamous Non–Small-Cell Lung Cancer

(2015) Hossein Borghaei et al.   NEW ENGLAND JOURNAL OF MEDICINE

The future of immune checkpoint therapy

(2015) P. Sharma et al.   SCIENCE

Soluble PD-1 aggravates progression of collagen-induced arthritis through Th1 and Th17 pathways

(2015) Cuiping Liu et al.   ARTHRITIS RESEARCH & THERAPY

The PD-1/PD-Ls pathway and autoimmune diseases

(2014) Suya Dai et al.   CELLULAR IMMUNOLOGY

Synovial T cell hyporesponsiveness to myeloid dendritic cells is reversed by preventing PD-1/PD-L1 interactions

(2014) Frederique M Moret et al.   ARTHRITIS RESEARCH & THERAPY

GSVA: gene set variation analysis for microarray and RNA-Seq data

(2013) Sonja Hänzelmann et al.   BMC BIOINFORMATICS

New learnings on the pathophysiology of RA from synovial biopsies

(2013) Costantino Pitzalis et al.   CURRENT OPINION IN RHEUMATOLOGY

Abatacept: A Review of its Use in the Management of Rheumatoid Arthritis

(2013) Gillian M. Keating   DRUGS

In Vivo Blockade of the Programmed Cell Death-1 Pathway Using Soluble Recombinant PD-1-Fc Enhances CD4+ and CD8+ T Cell Responses but Has Limited Clinical Benefit

(2013) P. K. Amancha et al.   JOURNAL OF IMMUNOLOGY

Adenovirus Expressing Both Thymidine Kinase and Soluble PD1 Enhances Antitumor Immunity by Strengthening CD8 T-cell Response

(2013) Seung-Pil Shin et al.   MOLECULAR THERAPY

Safety and Tumor Responses with Lambrolizumab (Anti–PD-1) in Melanoma

(2013) Omid Hamid et al.   NEW ENGLAND JOURNAL OF MEDICINE

Increased soluble programmed death-1 (sPD-1) is associated with disease activity and radiographic progression in early rheumatoid arthritis

(2013) SR Greisen et al.   SCANDINAVIAN JOURNAL OF RHEUMATOLOGY

Learning about the natural history of rheumatoid arthritis development through prospective study of subjects at high risk of rheumatoid arthritis-related autoimmunity

(2012) Kevin D. Deane   ARTHRITIS AND RHEUMATISM

Rheumatoid arthritis

(2010) David L Scott et al.   LANCET

Improved Survival with Ipilimumab in Patients with Metastatic Melanoma

(2010) F. Stephen Hodi et al.   NEW ENGLAND JOURNAL OF MEDICINE

Soluble PD-1 is Associated with Aberrant Regulation of T Cells Activation in Aplastic Anemia

(2009) Haijing Wu et al.   IMMUNOLOGICAL INVESTIGATIONS

Soluble PD-1 rescues the proliferative response of simian immunodeficiency virus-specific CD4 and CD8 T cells during chronic infection

(2008) Nattawat Onlamoon et al.   IMMUNOLOGY

Therapeutic T-cell manipulation in rheumatoid arthritis: past, present and future

(2008) J. D. Isaacs   RHEUMATOLOGY